Plant Name: Hypericum hirsutum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| RECQL; APOBEC3G; TDP1; PIK3CG; GLO1; GFER; HSD17B10; HPGD; ALOX15; ALDH1A1; USP2; POLB; APEX1; | |
| GAA; ACHE; | |
| TOP2A; | |
| INSR; SYK; FLT3; PIM1; MYLK; KDR; AURKB; AURKA; CDK8; CDK9; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA4; CA6; | |
| KDM4E; | |
| BACE1; | |
| HIF1A; | |
| NPC1; RAB9A; THPO; MAPT; APP; | |
| XDH; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | CDK9 | Cyclin-dependent kinase 9 | P50750 | CHEMBL3116 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.583E-13 | 9.375E-10 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.293E-12 | 1.153E-08 | CA1, CA12, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.895E-11 | 5.253E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.825E-11 | 5.253E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.972E-10 | 5.406E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.975E-10 | 8.438E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.286E-09 | 2.370E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.765E-09 | 3.726E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.275E-08 | 1.415E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.967E-08 | 2.846E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.347E-08 | 3.809E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.528E-06 | 5.367E-04 | INSR, KDR, SYK |
| BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 2.374E-06 | 7.952E-04 | APEX1, APP, AURKA, CYP1A1, INSR, USP2 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.980E-06 | 1.256E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 5.987E-06 | 1.786E-03 | CYP1B1, HIF1A, INSR, MAPT, SYK, XDH |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.108E-06 | 2.037E-03 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 7.908E-06 | 2.208E-03 | ALOX15, APP, FLT3, INSR, KDR, PIK3CG, SYK, THPO, XDH |
| BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 9.538E-06 | 2.504E-03 | ACHE, ALDH1A1, APOBEC3G, AURKA, AURKB, BACE1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, GAA, HSD17B10, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.050E-05 | 2.658E-03 | ALDH1A1, CYP19A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010647; positive regulation of cell communication | 1.897E-05 | 4.259E-03 | ALOX15, APP, CA2, CA7, CYP19A1, CYP1B1, FLT3, GPR35, HIF1A, INSR, KDR, PIK3CG, SYK, THPO, XDH |
| BP | GO:0023052; signaling | GO:0023056; positive regulation of signaling | 1.995E-05 | 4.433E-03 | ALOX15, APP, CA2, CA7, CYP19A1, CYP1B1, FLT3, GPR35, HIF1A, INSR, KDR, PIK3CG, SYK, THPO, XDH |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.129E-05 | 4.545E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.129E-05 | 4.545E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 2.219E-05 | 4.691E-03 | ALOX15, APP, CA2, CYP1A1, CYP1A2, HIF1A, NPC1 |
| BP | GO:0008152; metabolic process | GO:0043412; macromolecule modification | 2.737E-05 | 5.570E-03 | APEX1, APOBEC3G, APP, AURKA, AURKB, CDK8, CDK9, FLT3, HIF1A, HSD17B10, INSR, KDM4E, KDR, L3MBTL1, MYLK, NPC1, PIK3CG, PIM1, POLB, SYK, TOP2A, USP2 |
| BP | GO:0009987; cellular process | GO:0042981; regulation of apoptotic process | 3.105E-05 | 5.992E-03 | APEX1, AURKA, AURKB, CYP1B1, FLT3, GLO1, HIF1A, HPGD, KDR, MAPT, PIK3CG, PIM1, TOP2A, XDH |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.118E-05 | 5.992E-03 | AURKB, CA2, CA7, HIF1A, NPC1, SYK |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.137E-05 | 5.992E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 3.620E-05 | 6.679E-03 | ALOX15, APEX1, AURKA, CA2, CA9, CDK9, CYP1B1, HIF1A, MAPT, MYLK, POLB, RECQL, TDP1, TOP2A |
| CC | GO:0044464; cell part | GO:0044444; cytoplasmic part | 4.029E-05 | 7.372E-03 | ACHE, ALDH1A1, ALOX15, APEX1, APOBEC3G, APP, AURKA, AURKB, BACE1, CA1, CA2, CA4, CA7, CDK9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, FLT3, GAA, GFER, GLO1, HIF1A, HPGD, HSD17B10, INSR, KDR, MAPT, MYLK, NPC1, PIK3CG, PIM1, RAB9A, SYK, TOP2A, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.250E-05 | 7.495E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0051425; PTB domain binding | 4.250E-05 | 7.495E-03 | APP, INSR |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 4.580E-05 | 7.914E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0042592; homeostatic process | 4.841E-05 | 8.108E-03 | APEX1, APP, CA12, CA2, CA7, FLT3, GAA, GPR35, HIF1A, INSR, NPC1, PIK3CG, POLB |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.239E-05 | 8.642E-03 | APOBEC3G, CA1, CA12, CA2, CA4, CA6, CA7, CA9, GLO1, L3MBTL1 |
| BP | GO:0008283; cell proliferation | GO:0008283; cell proliferation | 5.598E-05 | 9.165E-03 | ACHE, AURKB, CDK9, CYP1A1, FLT3, PIK3CG, PIM1, SYK, THPO |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.948E-18 | 2.166E-13 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.835E-17 | 3.345E-15 | CA12; CA1; CA2; CA4; CA7; CA6; CA9; CA14 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.105E-08 | 6.518E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.908E-08 | 2.717E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.027E-07 | 1.188E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.161E-07 | 1.690E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.282E-06 | 2.521E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.564E-06 | 1.444E-04 | INSR; CYP1A1; CYP1B1; CYP19A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.100E-05 | 4.572E-04 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.833E-04 | 2.785E-03 | CYP2C9; GAA; CYP1A2; ALOX15; ALDH1A1; CYP1A1; CYP2C19; CYP3A4; CYP19A1; HSD17B10; XDH |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.051E-04 | 2.200E-03 | CYP2C9; APP; ALOX15; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.530E-04 | 1.806E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.393E-04 | 3.987E-03 | FLT3; PIM1; PIK3CG |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.626E-04 | 4.742E-03 | CYP2C9; ALOX15; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 7.062E-04 | 5.555E-03 | FLT3; HIF1A; PIK3CG |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 9.500E-04 | 7.006E-03 | BACE1; APP; MAPT; HSD17B10 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.441E-03 | 1.600E-02 | INSR; HIF1A; PIK3CG |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 3.936E-03 | 2.323E-02 | SYK; PIK3CG; MYLK |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 6.243E-03 | 3.272E-02 | SYK; INSR; PIK3CG |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 8.055E-03 | 3.802E-02 | THPO; PIM1; PIK3CG |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 9.367E-03 | 4.094E-02 | INSR; PIK3CG; MYLK |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.182E-02 | 4.447E-02 | SYK; INSR; KDR; PIK3CG |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.147E-02 | 4.447E-02 | CDK9; HPGD; FLT3 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.335E-03 | 4.094E-02 | INSR; PIK3CG |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 4.620E-03 | 2.596E-02 | INSR; PIK3CG |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 6.929E-03 | 3.407E-02 | INSR; PIK3CG |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.581E-02 | 4.788E-02 | KDR; HIF1A; PIK3CG |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.066E-02 | 4.447E-02 | HIF1A; PIK3CG |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.100E-02 | 4.447E-02 | KDR; PIK3CG |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.561E-02 | 4.788E-02 | KDR; PIK3CG; MYLK |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.623E-02 | 4.788E-02 | POLB; SYK; PIK3CG |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 6.378E-03 | 3.272E-02 | CYP3A4; XDH |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.354E-02 | 4.698E-02 | SYK; PIK3CG |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.206E-02 | 4.447E-02 | INSR; PIK3CG |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.549E-02 | 4.788E-02 | SYK; PIK3CG |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.279E-02 | 4.573E-02 | HIF1A; PIK3CG |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 3.325E-03 | 2.065E-02 | POLB; APEX1 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.589E-02 | 4.788E-02 | CA2; MYLK |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.620E-03 | 1.124E-02 | CA2; CA4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.469E-02 | 4.788E-02 | CA2; CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 6.597E-05 | 8.650E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PIK3CG |
| C00-D49: Neoplasms | Cancer | C00-C96 | KDR; SYK; HIF1A; PIK3CG; CA1; FLT3; FLT3; CA9; PIM1; APP; AURKA; ACHE |
| C00-D49: Neoplasms | Prostate cancer | C61 | PIK3CG; FLT3 |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKA; AURKB |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; PIK3CG |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; PIK3CG; PIK3CG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| NA: NA | Enthesopathy | NA | PIK3CG |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; APP; ACHE; ACHE; ACHE; MAPT |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | KDR; KDR; KDR; SYK; HIF1A; PIK3CG; FLT3; CA9; AURKA; TOP2A; AURKB |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Breast cancer | C50 | KDR; KDR; KDR; INSR; CYP19A1; PIK3CG; FLT3; FLT3; CA9 |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; HIF1A; PIK3CG; PIK3CG; CA9 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; MYLK |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| C00-D49: Neoplasms | Glioma | C71 | KDR; PIK3CG; APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PIK3CG |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; PIK3CG |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| NA: NA | Angioedema | NA | PIK3CG |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | PIK3CG |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; AURKB |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | KDR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | PIK3CG; PIK3CG; AURKA |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |